#Taiwan #Taipei #biotech company #HanchorBio #TWSE Innovation Board

HanchorBio's Strategic Leap Toward Global Expansion

HanchorBio, Inc., a prominent clinical-stage biotechnology firm, has made significant strides in its ambition to broaden its global presence. The company has received formal approval from the Board of Directors of the Taiwan Stock Exchange (TWSE) to list on the TWSE Innovation Board. This pivotal move is projected for the second quarter of 2026, contingent upon finalizing the customary procedures.

The importance of this transition is deeper than merely securing funding. It encapsulates a strategic milestone designed to bolster HanchorBio's foundation within capital markets as it embarks on its next growth phase. Central to this strategy is the global advancement of its clinical developments and the expansion of its proprietary Fc-Based Designer Biologics (FBDB™) platform. The company also aims to enhance its visibility among institutional investors and multinational partners, further fortifying its operational and governance structures to transition into a globally acknowledged biotechnology entity.

Founded in 2020, HanchorBio is dedicated to advancing immunology through scientifically grounded innovations. The firm’s FBDB™ platform is strategically developed to create multifunctional biologics that precisely target and modulate key immune pathways—overcoming the constraints typically found in conventional single-target methodologies.

HanchorBio is not simply focused on a single product but rather on a diversified portfolio of candidates, developed using innovative, AI-driven engineering strategies and comprehensive understanding of immunological mechanisms. This platform-centric model allows HanchorBio the strategic flexibility to create long-term value, effectively addressing numerous unmet medical needs across varied disease domains.

The vision of Scott Liu, PhD, the founder and CEO of HanchorBio, emphasizes the company’s broad ambitions. “HanchorBio was constructed with the intention of doing more than simply pushing individual programs forward. We’re cultivating a scientific discipline and scalable platform capable of generating innovative biologics that can result in significant global impact. Advancing toward the TWSE Innovation Board is crucial for bolstering our execution capabilities,” he remarked.

Among HanchorBio’s flagship oncology initiatives are HCB101 and HCB301, which underscore the range of HanchorBio's capabilities and commitment to pioneering advanced immunotherapies.

HCB101 serves as the leading candidate in innate immune checkpoint innovation and is currently undergoing clinical trials for solid tumor applications, having advanced to Phase 1b/2 studies. Its design targets the CD47-SIRPα axis while preserving a unique hematologic profile. In an important validation of both the asset and the company’s collaboration strategies, HanchorBio entered its inaugural regional licensing agreement for HCB101 in June 2025, with a potential total deal value of up to $202 million. The company is actively advancing HCB101 on a global scale alongside further strategic partnerships.

Conversely, HCB301 consists of a tri-specific fusion protein engineered via the FBDB™ platform to concurrently modulate SIRPα, PD-L1, and TGF-β within a single therapeutic entity. This candidate is currently in the early stages of clinical development, exemplifying HanchorBio's capacity to create multifunctional biologics that can influence multiple immunosuppressive pathways within the tumor microenvironment.

In addition to oncology-focused projects HCB101 and HCB301, HanchorBio is broadening its reach into autoimmune diseases through candidates such as HCB206 and HCB307. This expansion reflects the company’s ambitious long-term vision to apply its innovative immune-engineering capabilities across diverse therapeutic areas.

As HanchorBio gears up for the forthcoming TWSE Innovation Board listing, it is poised to continue its focus on advancing HCB101 and HCB301 through clinical stages, while further diversifying its pipeline in oncology and autoimmune sectors. The goal is to enhance the reach of the FBDB™ platform via strategic collaborations and internal development efforts. The anticipated TWSE Innovation Board listing is expected to facilitate broader institutional engagement, yield increased financial flexibility, and enhance visibility as HanchorBio pursues its long-term mission of global expansion in the biotech arena.

About HanchorBio

HanchorBio (TPEx: 7827) is a trailblazing global clinical-stage immunology firm headquartered across Taipei, Shanghai, and the San Francisco Bay Area. The company is committed to developing the next generation of multifunctional biologics targeting oncology and immune-mediated disorders. The proprietary FBDB™ platform stands at the center of its operations, empowering the design of innovative therapeutic candidates that effectively modulate immune responses. With a burgeoning pipeline, including notable candidates such as HCB101 and HCB301 and additional platform-derived projects like HCB206 and HCB307, HanchorBio is poised to tackle significant unmet medical challenges through exceptional scientific prowess and a forward-thinking developmental strategy. For more details about the company, visit HanchorBio.com.